NOVAN INC (NOVN) Stock Price, Quote, News and Overview
NASDAQ:NOVN - Nasdaq - US66988N2053 - Common Stock - Currency: USD
NOVN Quote, Performance and Key Statistics
0.0941
-0.03 (-24.84%)
The current stock price of NOVN is 0.0941 USD. In the past month the price decreased by -77.43%. In the past year, price decreased by -96.77%.
NOVN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About NOVN
Company Profile
Novan, Inc. is a medical dermatology company, which engages in the development and commercialization of therapeutic products for skin diseases. The company is headquartered in Durham, North Carolina and currently employs 89 full-time employees. The company went IPO on 2016-09-21. The firm is focused on developing and commercializing therapeutic products for skin diseases. The firm is engaged in developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, with a focus on molluscum contagiosum (molluscum). The firm's commercial portfolio includes six branded prescription drugs. The company actively promotes three medical dermatological products in the United States, such as Wynzora (calcipotriene and betamethasone dipropionate), Rhofade (oxymetazoline hydrochloride), and Minolira (minocycline hydrochloride). Wynzora is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis. Rhofade is an alpha1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema. Minolira is indicated to treat inflammatory lesions.
Company Info
NOVAN INC
4020 Stirrup Creek Drive, Suite 110
Durham NORTH CAROLINA 27703 US
CEO: Paula Brown Stafford
Employees: 89
Company Website: https://novan.com/
Phone: 19194858080.0
NOVAN INC / NOVN FAQ
What is the stock price of NOVAN INC today?
The current stock price of NOVN is 0.0941 USD. The price decreased by -24.84% in the last trading session.
What is the ticker symbol for NOVAN INC stock?
The exchange symbol of NOVAN INC is NOVN and it is listed on the Nasdaq exchange.
On which exchange is NOVN stock listed?
NOVN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NOVAN INC stock?
7 analysts have analysed NOVN and the average price target is 15.81 USD. This implies a price increase of 16701.28% is expected in the next year compared to the current price of 0.0941. Check the NOVAN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NOVAN INC worth?
NOVAN INC (NOVN) has a market capitalization of 2.64M USD. This makes NOVN a Nano Cap stock.
How many employees does NOVAN INC have?
NOVAN INC (NOVN) currently has 89 employees.
Is NOVAN INC (NOVN) expected to grow?
The Revenue of NOVAN INC (NOVN) is expected to grow by 19.34% in the next year. Check the estimates tab for more information on the NOVN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NOVAN INC (NOVN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NOVN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NOVN, evaluating the profitability, health, valuation and growth aspects
- NOVAN INC (NOVN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NOVAN INC (NOVN) Sales and EPS estimates to see what analysts future expectations are.
- NOVAN INC (NOVN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NOVAN INC (NOVN) Insider and Institutional Ownership to learn about the owners and their transactions.
- NOVAN INC (NOVN) Stock Chart to make your own analysis
- NOVAN INC (NOVN) Latest news and press-releases to stay up to date.
Does NOVAN INC (NOVN) stock pay dividends?
NOVN does not pay a dividend.
When does NOVAN INC (NOVN) report earnings?
NOVAN INC (NOVN) will report earnings on 2023-08-09, before the market open.
What is the Price/Earnings (PE) ratio of NOVAN INC (NOVN)?
NOVAN INC (NOVN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.51).
NOVN Technical Analysis
NOVN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NOVN. NOVN has a bad profitability rating. Also its financial health evaluation is rather negative.
NOVN Financial Highlights
Over the last trailing twelve months NOVN reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS increased by 21.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NOVN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to NOVN. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 78.75% and a revenue growth 19.34% for NOVN